This blow comes amid mounting pressure from cheaper, authorized copies of Novo's and Eli Lilly's medications. Meanwhile, ...

Vertex Pharmaceuticals seems likely to enjoy an end-of-year rebound ... The FDA is scheduled to announce its decision on ...

Recent health news highlights include a landmark ruling by the Inter-American Court of Human Rights concerning abortion ...

The Food and Drug Administration signed off on Vertex Pharmaceuticals' next-generation triple drug for cystic fibrosis late ...

A new CFTR modulator treatment called Alyftrek has been approved for people with CF ages 6 and older who have CFTR mutations ...

(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX) Friday announced that the U.S. Food and Drug Administration (FDA) has approved Alyftrek for treatment of cystic fibrosis.

The approval enables a small number of people with cystic fibrosis in the U.S. who were not previously eligible for a CFTR ...

Vertex Pharmaceuticals said Friday the U.S. Food and Drug Administration expanded its approval of a cystic fibrosis treatment, encompassing more patients with different types of mutations of the ...

Gilead Sciences, Inc. announced today that its executives will be speaking at the following investor conference: J.P. Morgan Healthcare Conference on Monday, January 13, 2025 beginning at 11:15 a.m.

Alyftrek is Vertex's fifth CFTR modulator to secure FDA approval. It is also under regulatory review in the European Union, the United Kingdom, Canada, Switzerland, Australia and New Zealand. Write to ...

Desktop Metal, Inc. ("Desktop Metal") today announced that it has filed a lawsuit against Nano Dimension Ltd. ("Nano Dimension") in the Delaware Court of Chancery (the "Court"), alleging that Nano ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...